汪宏斌, 刘宏侠①, 杨俊泉, 王晓红, 张 静, 高献书②. Stathmin在Ⅳ期非小细胞肺癌中表达及紫杉类化疗耐药相关性研究[J]. 中国肿瘤临床, 2009, 36(2): 101-105. DOI: 10.3969/j.issn.1000-8179.2009.02.011
引用本文: 汪宏斌, 刘宏侠①, 杨俊泉, 王晓红, 张 静, 高献书②. Stathmin在Ⅳ期非小细胞肺癌中表达及紫杉类化疗耐药相关性研究[J]. 中国肿瘤临床, 2009, 36(2): 101-105. DOI: 10.3969/j.issn.1000-8179.2009.02.011
shu
WANG Hongbin1, LIU Hongxia2, YANG Junquan1, ZHANG Jing1, GAO Xianshu3, . Relationship between Stathmin Expression and Taxane Resistance in StageⅣ Non-small Cell Lung Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 36(2): 101-105. DOI: 10.3969/j.issn.1000-8179.2009.02.011
Citation: WANG Hongbin1, LIU Hongxia2, YANG Junquan1, ZHANG Jing1, GAO Xianshu3, . Relationship between Stathmin Expression and Taxane Resistance in StageⅣ Non-small Cell Lung Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 36(2): 101-105. DOI: 10.3969/j.issn.1000-8179.2009.02.011
shu

Stathmin在Ⅳ期非小细胞肺癌中表达及紫杉类化疗耐药相关性研究

Relationship between Stathmin Expression and Taxane Resistance in StageⅣ Non-small Cell Lung Cancer

    摘要
  • 摘要: 目的：探讨Ⅳ期非小细胞肺癌（NSCLC ）Stathmin 蛋白表达与紫杉类化疗耐药性关系。方法：回顾性分析2003年10月～2007年10月75例接受以紫杉类化疗的Ⅳ期NSCLC 临床病理资料。免疫组织化学法检测肿瘤标本Stathmin 蛋白表达，并对化疗疗效及生存时间进行分析。结果：Stathmin 阳性表达（≥50% 阳性染色细胞）率为80.00% 60/75），男性高表达率为81.63% ，女性为76.92% ，P=0.627；鳞癌71.79% ，腺癌88.89% ，P=0.064；≥58岁78.95% ，<58岁81.08% ，P=0.817；化疗有效率（CR+PR）为34.67% ，Stathmin 高表达患者紫杉类化疗有效率低28.33%（17/60），进展率高21.67%（13/60），而Stathmin 低表达患者化疗有效率高60.00%（9/15），进展率低0（0/15），P=0.021和P=0.047。Stathmin 高表达者有较短的中位OS（12.0 个月）和PFS（8.0 个月），而Stathmin 低表达患者有较长的中位OS（17.0 个月）和PFS（13.0 个月），P=0.008 和P=0.008。患者性别、年龄和组织类型与中位OS及PFS 无相关性，P 值均>0.05。结论：Stathmin 高表达NSCLC 患者对紫杉类药物耐药且预后不良。

     

    Abstract: Objective:To investigate the expression of Stathmin protein and chemoresistance to taxane in non-small cell lung cancer (NSCLC). Methods:Seventy-five patients with stageⅣNSCLC treated with taxane between October 2003 and October 2007 were enrolled in the study and the tumor samples were retrospec-tively analyzed. The expression of Stathmin protein in the tumor samples was detected by immunohistochem -istry. Data regarding the effects of taxane treatment and survival time were collected and analyzed. Results: The positive staining rate of Stathmin ( ≥50% cells were stained) was 80.00% (60/75). The positive staining rate of Stathmin was 81.63% in male patients, 76.92% in female patients (P=0.627 ), 71.79% in pulmonary squamous cell carcinoma, 88.89% in pulmonary adenocarcinoma (P=0.064 ), 78.95% in patients over 58 years old, and 81.08% in patients of 58 years or younger ( P=0.817 ). The response rate (CR + PR) was 34.67%. Patients with Stathmin overexpression (>50% cells were stained) had a lower response rate to tax-ane of 28.33% (17/60) and a higher progression rate of 21.67% (13/60) after taxane treatment. Patients with Stathmin underexpression (< 50% cells were stained) had a higher response rate of60.00% (9/15) and a low-er progression rate of 0 (0/15) (P=0.021 and P=0.047 , respectively). Overexpression of Stathmin protein was correlated with shorter median overall survival (12.0 months) and progression-free survival (8.0 months). Low expression of Stathmin protein was correlated with longer median overall survival ( 17.0 months) and progres-sion-free survival (13.0 months) (P=0.008 and P=0.008 , respectively). Patient characteristics including age, gender, and histological subtype were not correlated with median overall survival or progression-free survival (P>0.05). Conclusion:Overexpression of Stathmin is associated with resistance to taxane and poor prognosis of NSCLC patients treated with taxane-based chemotherapy.

     

    • HTML全文
    • 参考文献(0)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回